Bingham Private Wealth’s AstraZeneca AZN Stock Holding History

Bingham Private Wealth’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$778K	Buy	4,104 +138	+3%	+$26K	0.54%	59
2026 Q1	$782K	Buy	3,966 +325	+9%	+$62.7K	0.62%	47
2025 Q4	$669K	Buy	+3,641	New	+$639K	0.58%	45
2025 Q2	$403K	Buy	2,886 +53	+2%	+$7.43K	0.38%	85
2025 Q1	$416K	Buy	2,833 +923	+48%	+$134K	0.43%	80
2024 Q4	$250K	Buy	+1,910	New	+$267K	0.27%	116

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bingham Private Wealth's AZN Position: Q2 2026 in Review

Bingham Private Wealth increased its AstraZeneca (AZN) stake by 3.5% in Q2 2026, buying an estimated $26K and bringing the position to 4,104 shares worth $778K. The position accounts for 0.54% of the portfolio, ranked #59.

Bingham Private Wealth first reported a position in AZN in Q4 2024 and has held it in 6 quarters since. The position peaked at $782K in Q1 2026. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Bingham Private Wealth held 4,104 shares of AstraZeneca worth $778K as of Q2 2026.
Bingham Private Wealth bought 138 AstraZeneca shares in Q2 2026, an estimated $26K.
AstraZeneca made up 0.54% of Bingham Private Wealth's portfolio in Q2 2026, its #59 holding.
Bingham Private Wealth first reported a position in AstraZeneca in Q4 2024 and has held it in 6 quarters since.
Bingham Private Wealth's AstraZeneca position peaked at $782K in Q1 2026.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Bingham Private Wealth's 13F filing for Q2 2026, filed 11 Aug 2026.